Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Recruiting N/A Interventional Study
Breast Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Interventional
Purpose
Diagnostic
Participants needed
300 (estimated)
Sponsor
M.D. Anderson Cancer Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer. To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detected cancers.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * The subjects to be studied will include female patients ages 18 and older of any race, identified as carrying an elevated risk for breast cancer referred to MDACC. * High risk may be defined as having a calculated lifetime risk \>20%, histopathology of lobular neoplasia or aty…
Contacts

Beatriz Adrada

(713) 792-2709

beatriz.adrada@mdanderson.org

CONTACT